Wilke Michael, Worf Kerstin, Preisendörfer Birgit, Heinlein Wolfgang, Kast Tilman, Bodmann Klaus-Friedrich
inspiring-health GmbH, Munich, Germany.
Klinikum Barnim GmbH, Werner Forßmann Krankenhaus, Eberswalde, Germany.
GMS Infect Dis. 2019 Oct 23;7:Doc03. doi: 10.3205/id000043. eCollection 2019.
Complicated infections such as osteomyelitis, skin and soft tissue infections or endocarditis often require antibiotic therapies that can last up to several weeks. The prolonged hospital length of stay (LOS) leads to a dramatic increase in costs. Single-dose intravenous Dalbavancin is a novel antimicrobial agent for the treatment of acute bacterial skin, skin structure and soft tissue infections (ABSSSI) that allows an earlier discharge of patients, resulting in potential savings. Joint, bone and prostheses infections (JBPI) are also related with long LOS. The aim of this study is to determine the economic effects of single-dose intravenous Dalbavancin in suitable patients with Methicillin-resistant infections in Germany. For this purpose, an analysis with real-world patient treatment data was performed, which was subsequently validated in a large German hospital. In total, ABSSSI patients with MRSA infections could stay 6.45 days shorter and 2,865 € could be saved while JBPI patients could be discharged eventually 10.6 days earlier and 3,909 € could be saved. Single-dose intravenous Dalbavancin is thus an option for patients with ABSSSI and JBPI who are eligible for discharge.
诸如骨髓炎、皮肤及软组织感染或心内膜炎等复杂感染通常需要持续数周的抗生素治疗。住院时间延长会导致成本大幅增加。单剂量静脉注射达巴万星是一种新型抗菌药物，用于治疗急性细菌性皮肤、皮肤结构及软组织感染（ABSSSI），可使患者更早出院，从而节省开支。关节、骨骼及假体感染（JBPI）也与住院时间长有关。本研究的目的是确定单剂量静脉注射达巴万星对德国合适的耐甲氧西林感染患者的经济影响。为此，利用真实世界患者治疗数据进行了分析，并随后在一家大型德国医院进行了验证。总体而言，耐甲氧西林金黄色葡萄球菌感染的ABSSSI患者住院时间可缩短6.45天，节省2865欧元，而JBPI患者最终可提前10.6天出院，节省3909欧元。因此，单剂量静脉注射达巴万星是适合出院的ABSSSI和JBPI患者的一种选择。
